ES3010832T3 - Use of tradipitant in motion sickness - Google Patents

Use of tradipitant in motion sickness Download PDF

Info

Publication number
ES3010832T3
ES3010832T3 ES19783926T ES19783926T ES3010832T3 ES 3010832 T3 ES3010832 T3 ES 3010832T3 ES 19783926 T ES19783926 T ES 19783926T ES 19783926 T ES19783926 T ES 19783926T ES 3010832 T3 ES3010832 T3 ES 3010832T3
Authority
ES
Spain
Prior art keywords
tradipitant
use according
pharmaceutical composition
motion sickness
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19783926T
Other languages
English (en)
Spanish (es)
Inventor
Mihael Polymeropoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Application granted granted Critical
Publication of ES3010832T3 publication Critical patent/ES3010832T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
ES19783926T 2018-09-28 2019-09-26 Use of tradipitant in motion sickness Active ES3010832T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737992P 2018-09-28 2018-09-28
US201962874927P 2019-07-16 2019-07-16
PCT/US2019/053107 WO2020069092A1 (en) 2018-09-28 2019-09-26 Use of tradipitant in motion sickness

Publications (1)

Publication Number Publication Date
ES3010832T3 true ES3010832T3 (en) 2025-04-04

Family

ID=68165866

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19783926T Active ES3010832T3 (en) 2018-09-28 2019-09-26 Use of tradipitant in motion sickness

Country Status (20)

Country Link
US (2) US20220249444A1 (https=)
EP (2) EP3856338B1 (https=)
JP (1) JP7468964B2 (https=)
KR (2) KR102863233B1 (https=)
CN (1) CN111918701B (https=)
AU (1) AU2019348001B2 (https=)
BR (1) BR112020015484A2 (https=)
CA (1) CA3089238A1 (https=)
CL (1) CL2020002165A1 (https=)
DK (1) DK3856338T3 (https=)
ES (1) ES3010832T3 (https=)
FI (1) FI3856338T3 (https=)
HR (1) HRP20250097T1 (https=)
HU (1) HUE070000T2 (https=)
IL (1) IL281569B2 (https=)
MX (1) MX2020008456A (https=)
PT (1) PT3856338T (https=)
SI (1) SI3856338T1 (https=)
WO (1) WO2020069092A1 (https=)
ZA (1) ZA202004594B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2824552T3 (es) * 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
JP7791832B2 (ja) 2020-03-26 2025-12-24 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
WO2023019084A1 (en) * 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1035115E (pt) * 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
AU2003230829B8 (en) * 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
BRPI0415010B8 (pt) * 2003-10-24 2021-05-25 Lilly Co Eli formas cristalinas iv e v de {2-[1-(3,5-bis-trifluorometilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il)-(2-clorofenil)-metanona, (2-clorofenil)-[2-(2-hidróxi-2-piridin-4-il-vinil)piridin-3-il]metanona, seus processos de preparação, e composição farmacêutica sólida
EP2722045B1 (en) * 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
ES2824552T3 (es) * 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
CN119074729A (zh) * 2017-11-17 2024-12-06 万达制药公司 使用川地匹坦治疗胃肠疾病的方法

Also Published As

Publication number Publication date
JP2022511194A (ja) 2022-01-31
JP7468964B2 (ja) 2024-04-16
EP3856338B1 (en) 2024-11-06
CL2020002165A1 (es) 2021-01-04
HRP20250097T1 (hr) 2025-03-28
CN111918701B (zh) 2024-08-02
BR112020015484A2 (pt) 2021-04-27
EP3856338A1 (en) 2021-08-04
NZ766397A (en) 2023-09-29
KR20250140634A (ko) 2025-09-25
CA3089238A1 (en) 2020-04-02
EP4450126A3 (en) 2025-02-19
SI3856338T1 (sl) 2025-04-30
US20240285588A1 (en) 2024-08-29
US20220249444A1 (en) 2022-08-11
IL281569A (en) 2021-05-31
HUE070000T2 (hu) 2025-04-28
AU2019348001A1 (en) 2020-08-06
AU2019348001B2 (en) 2023-09-21
EP4450126A2 (en) 2024-10-23
PT3856338T (pt) 2025-01-31
FI3856338T3 (fi) 2025-02-03
IL281569B2 (en) 2025-04-01
IL281569B1 (en) 2024-12-01
ZA202004594B (en) 2024-12-18
WO2020069092A1 (en) 2020-04-02
DK3856338T3 (da) 2025-02-10
CN111918701A (zh) 2020-11-10
MX2020008456A (es) 2020-09-25
KR20210067980A (ko) 2021-06-08
KR102863233B1 (ko) 2025-09-22

Similar Documents

Publication Publication Date Title
ES3010832T3 (en) Use of tradipitant in motion sickness
Jin et al. Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors
ES3032138T3 (en) Tradipitant for use in treating gastroparesis
Tattersall et al. The novel NK1 receptor antagonist MK–0869 (L–754,030) and its water soluble phosphoryl prodrug, L–758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets
US20210008037A1 (en) Use of tradipitant in motion sickness
Emmanouil et al. Advances in understanding the actions of nitrous oxide
Robichaud et al. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway
ES2333805T3 (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de nauseas y vomitos.
US20220096449A1 (en) Method of treatment with tradipitant
RS65091B1 (sr) Postupci za lečenje povećanja telesne težine indukovanog antipsihoticima
Champion et al. Nitric oxide release mediates vasodilator responses to endomorphin 1 but not nociceptin/OFQ in the hindquarters vascular bed of the rat
CA2357901A1 (en) Combination treatment for depression and anxiety
RU2808669C2 (ru) Применение традипитанта от укачивания
US20240299373A1 (en) Improved use of tradipitant in motion sickness
ES2285995T3 (es) Combinacion para el tratamiento de la depresion y ansiedad que contiene un antagonista del receptor de nk-1 que penetra en el snc y un agente antidepresivo o ansiolitico.
NZ766397B2 (en) Use of tradipitant in motion sickness
BR112019027889A2 (pt) método de tratamento e formas de dosagem do mesmo
ES2367481T3 (es) Uso de un antagonista del adrenoreceptor alfa2 para enfermedades relacionadas con el snc.
Berger et al. Cholinergic drugs as diagnostic and therapeutic tools in affective disorders
TW201216977A (en) Compositions and methods for improving brain function
CN111714509A (zh) 一种薯蓣皂甙在防治运动病的药物中的应用
Robert Enteral Sedation Agents
Rittenhouse Pharmacological properties of dynorphin A-(2-17) and structurally related novel peptides
Fan Role of κ-opioid receptors in development of physical dependence upon butorphanol in rats
Freye et al. Use of Potent Opioids for Chronic Pain Management